Category Archives: Pr Newswire

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

– EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU –– Studies include both biologic naïve and experienced patients – HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its global Phase 3 program, consisting of two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) […]

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Complete enrollment achieved nearly six months ahead of plan Top-line data now anticipated mid-2025 Addition of second-line cholangiocarcinoma arm to BOLSTER trial BASKING RIDGE, N.J., July 16, 2024 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and […]

Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to Calidi SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Mark Gilbert, MD, scientist emeritus at the National […]

Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary

MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed […]

Teladoc Health Introduces Pediatric, Adolescent and Family Mental Healthcare Through Partnership with Brightline

Seamless access to a comprehensive range of mental healthcare options provides swift, early intervention and treatment for kids and teens, reduces caregiver stress, promotes healthy lifestyle habits at an early age PURCHASE, NY, July 16, 2024 (GLOBE NEWSWIRE) — Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the availability of comprehensive […]

Bank of America Reports Second Quarter 2024 Financial Results

CHARLOTTE, N.C., July 16, 2024 /PRNewswire/ — Bank of America reported its second quarter 2024 financial results today. The news release, supplemental filing and investor presentation can be accessed at Bank of America’s Investor Relations website at https://investor.bankofamerica.com/quarterly-earnings. Investor Conference Call information:Chief Executive Officer Brian Moynihan and Chief Financial Officer Alastair Borthwick will discuss the […]

Metabolon Expands Library to Include 70 Pesticides, Advancing Human Exposome Insights through Metabolomics

MORRISVILLE, N.C., July 16, 2024 /PRNewswire/ — Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced the expansion of its metabolite library to include 70 pesticides, strengthening the company’s ability to provide comprehensive environmental exposure insights via metabolomics […]

Biosyngen’s BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal Carcinoma

SINGAPORE, July 16, 2024 /PRNewswire/ — Biosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has approved the initiation of a pivotal Phase ll clinical trial evaluating BRG01, the company’s autologous Epstein-Barr virus […]

JinkoSolar to Form a Joint Venture with RELC and VI in Saudi Arabia for Production of 10 GW of High-efficiency Solar Cells and Solar Modules

SHANGRAO, China, July 16, 2024 /PRNewswire/ — JinkoSolar Holding Co., Ltd. (“JinkoSolar” or the “Company”) (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that its indirectly majority-owned subsidiary, JinkoSolar Middle East DMCC (“Jinko Middle East“), has entered into a shareholders agreement (the “Agreement”) with Renewable Energy […]

3rd AUTISM EXPO Concludes Successfully with Celebration and Unity

SEOUL, South Korea, July 16, 2024 /PRNewswire/ — The 3rd AUTISM EXPO 2024 concluded on a high note, featuring a wide range of exhibits and diverse events that attracted enthusiastic participation from individuals with developmental disabilities, their families, and related organizations. 3rd AUTISM EXPO Concludes Successfully with Celebration and Unity Co-hosted by SurplusGLOBAL and the […]